NEWS

Bukwang received US FDA approval for phase 2 clinical study IND of Levovir, as a...

[February 5, 2021]

Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that they received US FDA approval for Levovir(active ingredient: Clevudine) , as COVID-19 treatment phase 2 clinical study IND. This is a randomized, placebo controlled and doubleiblind study for the 40 outpatients except the severe stage. This study has been designed to find out if Levovir would reduce the infectivity of the virus against placebo. Bukwang has already done 60 patients recruitment for the clinical trial of Levovir as a COVID-19 treatment in Korea. It was for the moderate COVID-19...

R&D

Bukwang received US FDA approval for phase 2 clinical study IND of Levovir, as a COVID-19 treatment.

[February 5, 2021]

Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that they received US FDA approval for Levovir(active ingredient: Clevudine) , as COVID...

PRODUCTS
COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...

|    ​Korean    |

7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square